Revvity shifts to AI-driven diagnostics, posting 11% organic revenue growth and strong cash flow.

Revvity is evolving from a traditional tools company into a diagnostics-focused, AI-enabled platform, achieving 11% organic revenue growth in its Diagnostics segment and mid-20% growth in software ARR. This growth offsets challenges from Life Sciences and China market exits. The company shows strong operating leverage with 13% EPS growth on 3% organic revenue growth and free cash flow conversion above 100%, supporting debt reduction and strategic reinvestment. Despite GAAP P/E suggesting a premium valuation, adjusted metrics indicate Revvity is undervalued, with potential upside from margin expansion and capital returns.

Revvity's transformation into an AI-driven diagnostics platform is gaining attention as the stock trades near its 52-week high on Pluang. As of Oct 22, 2026 20:21 WIB, RVTY is priced at USD 156.34 with a slight 0.17% decline for the day, maintaining a market cap of $17.48 billion. Investor interest remains strong with 100% buy orders and a typical hold time of 13 days, reflecting confidence in the company's growth trajectory.